Open Innovation Tackles NCDs in Africa
December 9, 2014 Editor
The Devex Impact website reported that to understand more about Africa’s increasing noncommunicable diseases (NCD) threat, we need to bring together the brightest scientific minds to work as a team rather than struggling alone to find answers. No single country in the region has enough researchers with the appropriate mix of skills required to tackle this challenge. GlaxoSmithKline is drawing on its research expertise to help kickstart the discovery of new and better treatments for NCDs. But its approach to tackling these diseases in Africa is turning the usual model of closely guarded research and development on its head with the establishment of the world’s first R&D “Open Lab” for NCDs in sub-Saharan Africa.
Click here to read the full article.
- Prevention and Management of Non-Communicable Disease: The IOC Consensus Statement, Lausanne 2013.
- Strategies to support non-communicable disease interventions
- New fund for young developing world innovators to tackle deadly global health conditions
- Global health: Lifting the burden
- A systematic review of the literature on self-management interventions and discussion of their potential relevance for people living with HIV in sub-Saharan Africa.
- Africa: Q&A – Omotade Akin Aina On Expanding PhDs in Africa
Categories: Open Innovation
Subscribe to our stories
- Giving Francophone African incubators the keys to accelerate growth entrepreneurship February 13, 2018
- Is acceleration the panacea for scaling growth entrepreneurs? Reflections from XL Africa February 13, 2018
- Why providing pre-seed and seed capital is the essential step to bringing West Africa and Sahel’s entrepreneurs to the next level February 13, 2018
- Global Investment Competitiveness: New Insights on FDI February 2, 2018
- BioInnovate Africa phase II launched February 2, 2018